Sampo plc, stock exchange release, 15 January 2026 at 8:30 am EET Sampo plc’s share buybacks 14 January 2026 On 14 January 2026, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  3,153 9.84 AQEU    128,695 9.84 CEUX  32,937 9.84 TQEX  168,633 9.85 XHELTOTAL 333,418 9.85  * rounded to two decimals                      On 5 November 2025, Sampo announced a share buyback programme of up to a maximum of EUR 150 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 6 November 2025,...

Reports Q4-2025 Production, Record Annual Production, Production Guidance Achieved & Operational Highlights Serabi Gold plc (“Serabi” or the “Company”) (AIM:SRB, TSX:SBI, OTCQX:SRBIF), the Brazilian focused gold mining and development company, is pleased to announce the Company’s fourth quarter production results and operating highlights for FY2025 (all financial amounts are expressed in U.S. dollars unless otherwise indicated). Q4-2025 OPERATIONAL HIGHLIGHTS & 2026 GUIDANCEQuarterly gold production of 11,534 ounces, a 15% increase from Q4-2024. Record annual gold production of 44,169 ounces, achieving production guidance and an 18% increase on FY2024 gold production. A total of 4,535 metres of horizontal development for the quarter, a 45% increase from Q4-2024. Cash held as at 31 December 2025 of $49.2 million, with a further...

Based on the successful tender, a passenger transport public service contract was signed on 10 September 2024 between the Ministry of Regional Development and Agriculture (hereinafter: “Ministry”) and OÜ TS Laevad (hereinafter: “TS Laevad”) for the provision of transport services for a period of seven years starting on 1 October 2026. According to the agreement, TS Laevad will provide passenger transport services on the Virtsu-Kuivastu and Rohuküla-Heltermaa ferry routes with four ferries belonging to TS Laevad and one additional state-owned ferry between 01.10.2026 and 30.09.2033. According to the same agreement, TS Laevad is obliged to provide a replacement vessel for the state-owned ferry if it is not completed by 01.10.2026. On 13.01.2026, the Ministry and TS Laevad signed an amendment to the agreement, according to which the ferry...

Myqorzo and Redemplo approved in ChinaApproval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi’s long-term commitment to China, reinforcing the ambition to provide transformative medicines to patients in disease areas with large unmet medical needsParis, January 15, 2026. The National Medical Products Administration in China has approved two Sanofi-licensed innovative medicines, Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), and Redemplo (plozasiran) for the reduction of triglyceride levels, in adult patients with familial chylomicronaemia syndrome (FCS) on the basis of dietary control. “We are pleased to bring Myqorzo and Redemplo to patients in Greater China. Both medicines represent important advances in treatment...

Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Dario Eklund, Chief Executive Officer of Santhera, commented: “As a proudly Switzerland-based business, securing Swissmedic approval represents an important achievement, and marks our seventh global marketing approval. We expect to launch AGAMREE in Switzerland later in 2026, in order to ensure timely access to this important therapy for DMD patients in the country.” The Swissmedic approval of AGAMREE was based on the data from the pivotal Phase 2b VISION-DMD study and assessment results from the European...

OSLO, Norway (15 January 2026) – TGS, a leading provider of energy data and intelligence, is pleased to announce APEX 1, a first-of-its-kind, next-generation multi-client long-offset Ocean Bottom Node (OBN) acquisition campaign in the Gulf of America. Node deployment for APEX 1 commenced in December 2025, and acquisition is expected to be completed in late Q2 2026. Early products are expected in Q3 2026 and final data delivery Q4 2027. APEX 1 sets a new benchmark for large-scale long offset multi-client seismic by deploying a denser node grid than previous ultra-long offset OBN programs and by being designed as a stand-alone exploration dataset, without reliance on underlying streamer seismic coverage.  APEX 1 is enabled by TGS’ Gemini™ enhanced frequency source and leverages the TGS’ deep expertise in long-offset OBN acquisition,...

Ad hoc announcement pursuant to Art. 53 LRBaar (Switzerland), 15 January 2026 Based on preliminary unaudited figures, Ascom reports for fiscal year 2025 net revenue of CHF 292.1 million, which is an increase of around 3.8% at constant currencies, and an EBITDA margin of around 11.5% to 12.0%. Ascom generated net revenue of CHF 292.1 million for fiscal year 2025 (2024: CHF 286.7 million), which reflects an increase of around 3.8% at constant currencies. At actual currencies, the generated revenue represents an increase of 1.9% compared to the previous year, based on preliminary unaudited figures. Revenue development in constant currencies showed an increase in all three regions. The best performance was achieved in the Region USA & Canada, with a revenue growth of 7.3%. The performance of this region was supported by one very large...

   AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR15 JANUARY 2026 RICHEMONT MAINTAINED STRONG MOMENTUM WITH SALES UP 11% AT CONSTANT RATES FOR ITS THIRD QUARTER ENDED 31 DECEMBER 2025 Highlights for the quarter ended 31 December 2025Very solid calendar year end with Group Q3 sales of € 6.4 billion, up by 11% at constant exchange rates against demanding double-digit comparatives in prior-year period; Q3 sales up by 4% at actual ratesContinued strength at Jewellery Maisons, with sales up by 14% at constant rates; further improvement at Specialist Watchmakers, up by 7%; stable ‘Other’ sales, with Fashion & Accessories Maisons up by 3% Growth across all regions at constant exchange rates, with notable double-digit performances in the Americas, Japan and Middle East & Africa Solid growth across all distribution channels led by retail,...

MONTREAL, Jan. 14, 2026 (GLOBE NEWSWIRE) — Velan Inc. (TSX: VLN) (“Velan” or the “Company”) today announced that its controlling shareholder, Velan Holding Co. Ltd. (“Velan Holding”), the sole holder of the Company’s multiple voting shares, has agreed to sell its 15,566,567 multiple voting shares and one subordinate voting share (representing approximately 72.1% of the Company’s outstanding shares and 92.8% of its aggregate voting rights) to funds managed by Birch Hill Equity Partners Management Inc. (“Birch Hill”), at a price of C$13.10 per share, for aggregate gross proceeds of C$203,922,040.80 to Velan Holding and two other entities associated with shareholders of Velan Holding (the “VH Transaction”). Birch Hill is a leading Canadian investment partner with a 30-year track record of deploying patient capital and operational...